SCHEMBL5066955

SCHEMBL5066955

CSc1ncc2cc(-c3cc(NC(=O)Nc4cc(C(C)(C)C)no4)ccc3C)c(=O)n(C)c2n1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 6/20 0.46
SYK P43405 1/20 0.45
KDR P35968 3/20 0.43
NTRK1 P04629 2/20 0.43
RET P07949 1/20 0.43
EPHB2 P29323 1/20 0.43
CSF1R P07333 1/20 0.42
RAF1 P04049 5/20 0.41
BRAF P15056 5/20 0.40
KRAS P01116 2/20 0.40
MAP2K2 P36507 2/20 0.40
MAP2K1 Q02750 2/20 0.40
NEK7 Q8TDX7 2/20 0.39
FLT3 P36888 1/20 0.39
ALDH1A1 P00352 1/20 0.39
NTRK3 Q16288 1/20 0.38
NTRK2 Q16620 1/20 0.38
MAPK13 O15264 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrogen Sulfide SCHEMBL4279430 1.00 MAPK14 (0.46) MAPK14SYKKDRNTRK1RET
Hydrogen Sulfide SCHEMBL5062476 1.00 MAPK14 (0.46) MAPK14SYKKDRNTRK1RET
SCHEMBL5062687 0.88 RAF1 (0.51) MAPK14SYKKDRNTRK1RET
SCHEMBL5062732 0.87 BRAF (0.54) MAPK14KDRNTRK1RETEPHB2
SCHEMBL4552696 0.86 FLT3 (0.46) MAPK14SYKRETCSF1RFLT3
SCHEMBL4420333 0.85 MAPK14 (0.46) MAPK14SYKCSF1RRAF1BRAF
SCHEMBL5063013 0.81 SYK (0.45) MAPK14SYKKDRRETEPHB2
SCHEMBL5062481 0.81 BRAF (0.61) MAPK14KDRNTRK1RETEPHB2
SCHEMBL5065266 0.81 BRAF (0.46) MAPK14KDRNTRK1RETEPHB2
SCHEMBL4279468 0.80 BRAF (0.52) MAPK14SYKKDRRAF1BRAF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120289540-A1 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES DECIPHERA PHARMACEUTICALS, LLC (US) 2012-11-15 US disclosed
US-8188113-B2 For example, 1-(5-(2-amino-8-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-6-yl)-2-fluorophenyl)-3-(3-tert-butyl-1-phenyl-1H-pyrazol-5-yl)urea; for treatment of mammalian cancers and inflammatory diseases including rheumatoid arthritis, retinopathies DECIPHERA PHARMACEUTICALS, INC. (US) 2012-05-29 US disclosed
US-20080114006-A1 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PARMACEUTICALS, LLC (US) 2008-05-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120289540-A1 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES BRAF, PRKDC, RAF1 MAPK14 240/4885SYK 898/4885KDR 500/4885
US-20080114006-A1 Kinase inhibitors useful for the treatment of proliferative diseases BRAF, PRKDC, RAF1 MAPK14 240/4885SYK 898/4885KDR 500/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.